

# James Mu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1476234/publications.pdf>

Version: 2024-02-01

43  
papers

11,028  
citations

126907

33  
h-index

254184

43  
g-index

44  
all docs

44  
docs citations

44  
times ranked

13391  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists. <i>Nature Communications</i> , 2022, 13, 942.	12.8	17
2	Discovery of Insulin Receptor Partial Agonists MK-5160 and MK-1092 as Novel Basal Insulins with Potential to Improve Therapeutic Index. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5593-5605.	6.4	8
3	In Situ Forming Injectable Thermoresponsive Hydrogels for Controlled Delivery of Biomacromolecules. <i>ACS Omega</i> , 2020, 5, 17531-17542.	3.5	36
4	Restoration of insulin receptor improves diabetic phenotype in T2DM mice. <i>JCI Insight</i> , 2019, 4, .	5.0	16
5	Engineering Glucose Responsiveness Into Insulin. <i>Diabetes</i> , 2018, 67, 299-308.	0.6	54
6	A glucose-responsive insulin therapy protects animals against hypoglycemia. <i>JCI Insight</i> , 2018, 3, .	5.0	31
7	Potential of Insulin-Mediated Glucose Lowering without Elevated Hypoglycemia Risk by a Small Molecule Insulin Receptor Modulator. <i>PLoS ONE</i> , 2015, 10, e0122012.	2.5	7
8	Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 954-957.	4.4	17
9	Downstream Signaling Pathways in Mouse Adipose Tissues Following Acute In Vivo Administration of Fibroblast Growth Factor 21. <i>PLoS ONE</i> , 2013, 8, e73011.	2.5	48
10	FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents. <i>Diabetes</i> , 2012, 61, 505-512.	0.6	148
11	The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin. <i>Obesity</i> , 2012, 20, 1566-1571.	3.0	90
12	Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist. <i>PLoS ONE</i> , 2012, 7, e49572.	2.5	47
13	Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice. <i>Diabetologia</i> , 2011, 54, 2381-2391.	6.3	57
14	Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. <i>European Journal of Pharmacology</i> , 2009, 623, 148-154.	3.5	120
15	PANIC-ATTAC: A Mouse Model for Inducible and Reversible $\beta^2$ -Cell Ablation. <i>Diabetes</i> , 2008, 57, 2137-2148.	0.6	59
16	Adipose Fibroblast Growth Factor 21 Is Up-Regulated by Peroxisome Proliferator-Activated Receptor $\beta^3$ and Altered Metabolic States. <i>Molecular Pharmacology</i> , 2008, 74, 403-412.	2.3	260
17	Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. <i>Diabetologia</i> , 2006, 50, 142-150.	6.3	182
18	Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic $\beta$ -Cell Mass and Function in a Rodent Model of Type 2 Diabetes. <i>Diabetes</i> , 2006, 55, 1695-1704.	0.6	432

#	ARTICLE	IF	CITATIONS
19	AMP-Activated Protein Kinase Induces a p53-Dependent Metabolic Checkpoint. <i>Molecular Cell</i> , 2005, 18, 283-293.	9.7	1,431
20	AMP kinase is not required for the GLUT4 response to exercise and denervation in skeletal muscle. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E739-E743.	3.5	57
21	The PP2A-Associated Protein $\hat{A}$ Is an Essential Inhibitor of Apoptosis. <i>Science</i> , 2004, 306, 695-698.	12.6	142
22	AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. <i>Nature</i> , 2004, 428, 569-574.	27.8	1,464
23	AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. <i>Journal of Clinical Investigation</i> , 2004, 114, 495-503.	8.2	640
24	Role of AMP-activated Protein Kinase in Cyclic AMP-dependent Lipolysis In 3T3-L1 Adipocytes. <i>Journal of Biological Chemistry</i> , 2003, 278, 43074-43080.	3.4	254
25	Isoform-specific Regulation of Insulin-dependent Glucose Uptake by Akt/Protein Kinase B. <i>Journal of Biological Chemistry</i> , 2003, 278, 49530-49536.	3.4	268
26	Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. <i>Biochemical Society Transactions</i> , 2003, 31, 216-219.	3.4	215
27	Selective suppression of AMP-activated protein kinase in skeletal muscle: update on "lazy mice"™. <i>Biochemical Society Transactions</i> , 2003, 31, 236-241.	3.4	93
28	The AMP-activated protein kinase $\hat{1}\pm 2$ catalytic subunit controls whole-body insulin sensitivity. <i>Journal of Clinical Investigation</i> , 2003, 111, 91-98.	8.2	444
29	GLUT4, AMP kinase, but not the insulin receptor, are required for hepatoportal glucose sensor-stimulated muscle glucose utilization. <i>Journal of Clinical Investigation</i> , 2003, 111, 1555-1562.	8.2	50
30	GLUT4, AMP kinase, but not the insulin receptor, are required for hepatoportal glucose sensor-stimulated muscle glucose utilization. <i>Journal of Clinical Investigation</i> , 2003, 111, 1555-1562.	8.2	31
31	AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 15983-15987.	7.1	895
32	Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKB $\beta$ ). <i>Science</i> , 2001, 292, 1728-1731.	12.6	1,652
33	The Regulation of AMP-Activated Protein Kinase by H <sub>2</sub> O <sub>2</sub> . <i>Biochemical and Biophysical Research Communications</i> , 2001, 287, 92-97.	2.1	269
34	A Role for AMP-Activated Protein Kinase in Contraction- and Hypoxia-Regulated Glucose Transport in Skeletal Muscle. <i>Molecular Cell</i> , 2001, 7, 1085-1094.	9.7	845
35	Glycogenin-2, a novel self-glucosylating protein involved in liver glycogen biosynthesis.. <i>Journal of Biological Chemistry</i> , 2001, 276, 14532.	3.4	2
36	Exercise Induces Isoform-Specific Increase in $\hat{5}$ AMP-Activated Protein Kinase Activity in Human Skeletal Muscle. <i>Biochemical and Biophysical Research Communications</i> , 2000, 273, 1150-1155.	2.1	318

#	ARTICLE	IF	CITATIONS
37	Structure and chromosomal localization of the human glycogenin-2 gene GYG2. <i>Gene</i> , 2000, 242, 229-235.	2.2	14
38	Self-Glycosylation of Glycogenin, the Initiator of Glycogen Biosynthesis, Involves an Inter-subunit Reaction. <i>Archives of Biochemistry and Biophysics</i> , 1999, 363, 163-170.	3.0	36
39	Novel Aspects of the Regulation of Glycogen Storage. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 1998, 9, 139-51.	1.3	55
40	Characterization of Human Glycogenin-2, a Self-glycosylating Initiator of Liver Glycogen Metabolism. <i>Journal of Biological Chemistry</i> , 1998, 273, 34850-34856.	3.4	34
41	Glycogenin-2, a Novel Self-glycosylating Protein Involved in Liver Glycogen Biosynthesis. <i>Journal of Biological Chemistry</i> , 1997, 272, 27589-27597.	3.4	51
42	Initiation of Glycogen Synthesis in Yeast. <i>Journal of Biological Chemistry</i> , 1996, 271, 26554-26560.	3.4	30
43	Requirement of the Self-Glycosylating Initiator Proteins Glg1p and Glg2p for Glycogen Accumulation in <i>Saccharomyces cerevisiae</i> . <i>Molecular and Cellular Biology</i> , 1995, 15, 6632-6640.	2.3	109